FCCC LOGO Faculty Publications
Swetter SM , Thompson JA , Albertini MR , Barker CA , Baumgartner J , Boland G , Chmielowski B , DiMaio D , Durham A , Fields RC , Fleming MD , Galan A , Gastman B , Grossmann K , Guild S , Holder A , Johnson D , Joseph RW , Karakousis G , Kendra K , Lange JR , Lanning R , Margolin K , Olszanski AJ , Ott PA , Ross MI , Salama AK , Sharma R , Skitzki J , Sosman J , Wuthrick E , McMillian NR , Engh AM
NCCN Guidelines(R) Insights: Melanoma: Cutaneous, Version 2.2021
J Natl Compr Canc Netw. 2021 Apr 1;19(4) :364-376
Back to previous list
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modifications of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Swetter, Susan M Thompson, John A Albertini, Mark R Barker, Christopher A Baumgartner, Joel Boland, Genevieve Chmielowski, Bartosz DiMaio, Dominick Durham, Alison Fields, Ryan C Fleming, Martin D Galan, Anjela Gastman, Brian Grossmann, Kenneth Guild, Samantha Holder, Ashley Johnson, Douglas Joseph, Richard W Karakousis, Giorgos Kendra, Kari Lange, Julie R Lanning, Ryan Margolin, Kim Olszanski, Anthony J Ott, Patrick A Ross, Merrick I Salama, April K Sharma, Rohit Skitzki, Joseph Sosman, Jeffrey Wuthrick, Evan McMillian, Nicole R Engh, Anita M eng J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. doi: 10.6004/jnccn.2021.0018.